Subcutaneous Entyvio hits Crohn’s primary endpoint, misses secondary
If approved, the drug could have huge benefits for patients as they could self-administer their therapy from home.
Read More
Tag: Entyvio
Entyvio beats Humira in head-to-head ulcerative colitis trial
Results offer new insight to support treatment decisions, Takeda says
Read More
EMA accepts Takeda application for subcutaneous Entyvio
The company proposes to make it available in both pre-filled syringe and pen options.
Read More
Takeda’s Entyvio bests AbbVie’s Humira in ulcerative colitis trial
Takeda’s Entyvio has beaten AbbVie’s Humira on achieving clinical remission in patients with ulcerative colitis, in the first trial to directly compare the efficacy and safety of two commonly used biologics for the disease.
Read More
Sub-cutaneous form of Entyvio hits PhIII safety, efficacy goals
Takeda says it has late-stage trial results showing the benefit of an investigational subcutaneous formulation of Entyvio to patients with ulcerative colitis.
Read More
New analysis backs use of Takeda’s Entyvio
Takeda has presented data from a post-hoc analysis showing signs of early symptomatic improvement in patients with ulcerative colitis or Crohn’s disease taking Entyvio.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
